Sentences with phrase «tumor research program»

Canine Brain Tumor Treatment and Brain Tumor MRI Research Program The PVM Canine Brain Tumor Research Program is a research program involving all aspects of canine brain tumor research: diagnosis using MRI, surgery, chemotherapy and other post-operative therapies.

He is the director of the Canine Brain Tumor Research Program, a program investigating many aspects of canine brain tumors, including diagnosis, surgery, and chemotherapy.

Not exact matches

PDX models are created by implanting cancerous tissue from a human primary tumor directly into immunodeficient mouse or rat models, enabling acceleration of oncology research or drug discovery and development programs.

«We are looking to optimize the combinations of targeted therapies and the scheduling of those therapies so we can improve tumor shrinkage and minimize potential toxicities for a patient,» said Andrew Aplin, PhD, Associate Director for Basic Research and the Program Leader for Cancer Cell Biology and Signaling (CCBS) in the NCI - designated Sidney Kimmel Cancer Center at Jefferson Health.

«A deeper analysis of the primary tumor may be all we need to prevent metastases,» said UNC Lineberger's Lisa A. Carey, MD, physician - in - chief of the N.C. Cancer Hospital and the Richardson and Marilyn Jacobs Preyer Distinguished Professor in Breast Cancer Research, who leads the Tumor Donation Protumor may be all we need to prevent metastases,» said UNC Lineberger's Lisa A. Carey, MD, physician - in - chief of the N.C. Cancer Hospital and the Richardson and Marilyn Jacobs Preyer Distinguished Professor in Breast Cancer Research, who leads the Tumor Donation ProTumor Donation Program.

New research shows that microRNA - 486 is a potent tumor - suppressor molecule in lung cancer, and that the it helps regulate the proliferation and migration of lung - cancer cells, and the induction of programmed cell death, or apoptosis, in those cells.

«The treatment of multiple myeloma has improved significantly in recent years with the introduction of therapies such as proteasome inhibitors [which interfere with tumor cells» protein - disposal system] and potent immuno - modulatory agents,» said the paper's senior author and lead investigator, Paul Richardson, MD, clinical program leader and director of clinical research at Dana - Farber's Jerome Lipper Multiple Myeloma Center, and the R.J. Corman professor at Harvard Medical School.

«Pancreatic cancer cells are deadly because they program nearby immune cells to permit the tumors to survive and grow,» says study author George Miller, MD, head of the Cancer Immunology Program at Perlmutter and vice chair for research in the Department of Surgery at NYU Lprogram nearby immune cells to permit the tumors to survive and grow,» says study author George Miller, MD, head of the Cancer Immunology Program at Perlmutter and vice chair for research in the Department of Surgery at NYU LProgram at Perlmutter and vice chair for research in the Department of Surgery at NYU Langone.

According to University of Helsinki scientist and Finnish Academy Research Fellow Juha Klefström, PhD, who led the study, «Myc oncoprotein not only boosts tumor cell proliferation but it also makes the cells vulnerable to cell suicide program, apoptosis.

Joining forces with dermatologists and oncologists from the University Hospital in Zurich and backed by the University Research Priority Program «Translational Cancer Research,» Sommer's team was able to demonstrate that, in melanoma cells, the epigenetic factor EZH2 controls genes that govern tumor growth as well as genes that are important for the formation of metastases.

«This aspect of the research is one of the most intriguing findings to come out of the TCGA program, which has been looking at more than 30 tumor types over the past decade.»

The research was supported by the National Cancer Institute, Specialized Programs of Research Excellence (SPORE) grant, National Institutes of Health, the Dermatology Foundation, the Children's Tumor Foundation, and the Burroughs Wellcoresearch was supported by the National Cancer Institute, Specialized Programs of Research Excellence (SPORE) grant, National Institutes of Health, the Dermatology Foundation, the Children's Tumor Foundation, and the Burroughs WellcoResearch Excellence (SPORE) grant, National Institutes of Health, the Dermatology Foundation, the Children's Tumor Foundation, and the Burroughs Wellcome Fund.

«Our research shows that the protein GSK3 plays a crucial role in helping B cells meet the energy needs of their distinct states,» says Robert Rickert, Ph.D., director of the Tumor Microenvironment and Cancer Immunology Program at Sanford Burnham Prebys Medical Discovery Institute (SBP).

This is an unusually large amount of drivers, not typical for many other tumor types, according the study's senior author Dr. Matthew Wilkerson, associate professor and Bioinformatics Director of The American Genome Center and the Collaborative Health Initiative Research Program at USU.

«RNAi therapies are a unique approach to cancer treatment as they have the potential to «turn off» the genes» coding for proteins involved in cancer cell division,» said Ramesh K. Ramanathan, M.D., medical director of the Virginia G. Piper Cancer Center Clinical Trials Program at Scottsdale Healthcare and deputy director of the Clinical Translational Research Division of the Translational Genomics Research Institute (TGen) in Phoenix, Ariz. «Using a lipid nanoparticle, the RNAi drug can be delivered to a cancer cell to block the expression of specific proteins involved in tumor growth.»

Dr. Kunle Odunsi is the deputy director of the Roswell Park Cancer Institute, where he also serves as the chair of the Department of Gynecologic Oncology, the executive director of the Center for Immunotherapy, and the co-Leader of the Tumor Immunology and Immunotherapy research program.

Cancer Research Institute inaugurates its Investigator Award Program for junior faculty members working in immunology and tumor immunology.

My research program is centered around pediatric brain tumors and aims at elucidating genetic signatures of pediatric astrocytomas and examining how they compare to adults.

Co-Leader, Host - Tumor Interactions Research Program Louise B. McGavock Professor of Pathology, Microbiology and Immunology Assistant Vice Chancellor for Integrative Diagnostics

For 2018, the CIMT program committee is preparing plenary sessions from pre-clinical research to clinical development on the topics of therapeutic vaccination, cellular therapy, improving immunity, tumor microenvironment, antibodies, regulatory research and immunoguiding.

Research in the Immunology, Microenvironment and Metastasis program is aimed at 1) merging basic mechanistic understanding of multidisciplinary pathways of host - tumor interactions and metastatic dissemination with novel translational opportunities for diseases diagnosis and immunotherapy, as well as 2) investigating mechanisms regulating immune responses in cancer and their potential therapeutic manipulation.

Dr. Jason Yustein's laboratory is part of the Sarcoma Research Labs of the Bone Tumor Program and Ewing Sarcoma Center.

We are also one of the nation's largest multidisciplinary programs caring for children with solid tumors, and have the largest pediatric oncology research effort in the state.

In addition to her expertise in tumor biology and a broad network of connections with leading scientists and clinicians in cancer research and clinical oncology, Dr. Almog has extensive hands - on experience with a variety of techniques ranging from the molecular level (DNA, RNA and proteins) to tissue, organ and mouse models in cancer biology, as well as extensive experience in project management and program coordination.

Background In our institute, the first research program on disseminated tumor cells (DTC) detection in the bone marrow of early breast cancer patients was initiated in the late 90's; with about a thousand patients included, we constituted one of the largest cohort ever reported and contributed to the landmark report that established bone marrow DTC as a level - of - evidence 1 prognostic factor in early breast cancer (Braun, N Engl J Med 2005).

Young Kim, M.D., Ph.D., Associate Professor of Otolaryngology and co-leader of the Translational Research and Interventional Oncology Research Program, is a clinician - scientist focused on the development of immunotherapeutic modalities for solid tumors.

Faculty in the Brain and Spinal Tumor Program focus on clinical research and treatment of primary brain tumors, neoplastic meningitis, brain metastases, epidural cord compression, neurotoxicities, anticancer agents, and cancer pain management.

CRI Scientific Advisory Council director Lloyd J. Old, M.D., a pioneer responsible for many seminal discoveries in the field, is a senior expert in tumor immunology who for the past four decades has guided the scientific vision for CRI and who currently leads the Institute's global cancer vaccine research programs.

New data and research approaches have created opportunities for researchers to study in detail many aspects of cancer biology, including how the normal biological programs of cell proliferation and death are altered during cancer and how the immune system responds to tumors.

This is a structured program in which trainees receive in - depth education through a core clinical research curriculum and participation in clinical research training in one of five specialized training tracks: clinical pharmacology, neuro - oncology, cell and gene therapy, leukemia or solid tumor.

Old, who also heads the Ludwig Institute for Cancer Research (LICR) New York Branch and has served for many years as director of LICR's worldwide scientific programs, says that, eventually, vaccines will treat a wide variety of cancer types, recruiting the immune system to stop the progression of patients» tumors and helping to fully stabilizing the disease.

In 2016, Dmitry I. Gabrilovich, M.D., Ph.D., program leader of Wistar's Translational Tumor Immunology program, and his research team identified a marker for myeloid - derived suppressor cells (MDSCs), a population of immune cells implicated in tumor resistance to various types of cancer treatment, including targeted therapies, chemotherapy and immunotheTumor Immunology program, and his research team identified a marker for myeloid - derived suppressor cells (MDSCs), a population of immune cells implicated in tumor resistance to various types of cancer treatment, including targeted therapies, chemotherapy and immunothetumor resistance to various types of cancer treatment, including targeted therapies, chemotherapy and immunotherapy.

Tags: Andrew Hsieh, Biostatistics and Biomathematics Program, Cancer etiology - prevention - outcomes, Cancer Prevention Program, Cancer Surveillance System, Christopher J Kemp, Good News, Kevin Cheung, Marian Neuhouser, metastatic breast cancer, Peggy Porter, Peter Nelson, Public Health Sciences, Roland Walter, Ruth Etzioni, Sage Bionetworks, SCCA, Seattle Cancer Care Alliance (SCCA), Seattle Translational Tumor Research, STTR cancer, Tumor specific translational research, UW Research, STTR cancer, Tumor specific translational research, UW research, UW Medicine

Dr. Altieri also leads a research program that studies how tumor cells evade programmed cell death and the role of mitochondria, power plant of the cells, in tumor metabolism.

My research program focused on new interactions of adenosine (product of ATP) and TGFβ signaling during tumor progression.

Programs are clustered into Discipline - Based or Disease - Oriented and bring together investigators from all research disciplines (basic, population focused, and clinical) to tackle the challenges of tumor development and progression, diagnosis and treatment, as well as cancer control and disparities.

Sorenmo's Canine Mammary Tumor program at the University of Pennsylvania's Ryan Veterinary Hospital, in partnership with Princeton University, has now enrolled about 145 «underdogs,» offering them needed surgeries, collecting tumor tissue for the ongoing genomic studies, and placing them in new homes that will help with follow - up reseTumor program at the University of Pennsylvania's Ryan Veterinary Hospital, in partnership with Princeton University, has now enrolled about 145 «underdogs,» offering them needed surgeries, collecting tumor tissue for the ongoing genomic studies, and placing them in new homes that will help with follow - up resetumor tissue for the ongoing genomic studies, and placing them in new homes that will help with follow - up research.